Bivatuzumab (Anti-CD44v6)

Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD.
Supplier Selleck Chemicals
Product # A2555
Sku # A2555-1mg
Pricing 1mg, $270.00
Feedback